Wellbutrin SR/Zyban Generics Will Not Be Blocked By Andrx Exclusivity
Executive Summary
Andrx will allow Teva/Impax to launch a generic version of GlaxoSmithKline's Wellbutrin SR/Zyban (bupropion sustained-release) if FDA does not approve Andrx' ANDA within a "defined period of time.
You may also be interested in...
Wellbutrin SR Generics Multiply As Andrx Relinquishes Exclusivity
Andrx' agreement to give up its first-to-file ANDA exclusivity on a generic of GlaxoSmithKline's Wellbutrin SR 150 mg tablet means six companies will immediately share in the profits on sales of the generic antidepressant
Wellbutrin SR Generics Multiply As Andrx Relinquishes Exclusivity
Andrx' agreement to give up its first-to-file ANDA exclusivity on a generic of GlaxoSmithKline's Wellbutrin SR 150 mg tablet means six companies will immediately share in the profits on sales of the generic antidepressant
Impax/Teva Wellbutrin SR Generic Cleared To Launch By Court, FDA
Impax' bupropion sustained-release generic is cleared for launch following an appeals court ruling that the company does not infringe GlaxoSmithKline's Wellbutrin SR/Zyban patent